Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06288633Not ApplicableRecruiting

Cardioneuroablation for Bradyarrhythmia

Role: collaborator

NCT06127992Not ApplicableUnknown

Non-invasive Diagnosis of Cold Urticaria

Role: lead

NCT05982704Phase 4Unknown

Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19

Role: lead

NCT05302947Completed

COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU

Role: collaborator

All 4 trials loaded